The Pharma Data

DECEMBER 29, 2020

Primary Aldosteronism Testing Rare in Treatment-Resistant HTN. 29, 2020 — Patients with apparent treatment-resistant hypertension are rarely tested for primary aldosteronism, according to a study published online Dec. Veterans Health Administration with apparent treatment-resistant hypertension from 2000 to 2017.

Treatment 52

Treatment International Therapies Research 52

Broad Institute

OCTOBER 4, 2023

Researchers from the Tumor Immunotherapy Discovery Engine ( TIDE ) at the Broad Institute of MIT and Harvard, AbbVie, and Calico Life Sciences report that the molecule simultaneously makes tumors more sensitive to immune attack and boosts the activity of immune cells to fight tumors in mice.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

Conversations in Drug Development Trends

AUGUST 10, 2023

As one of the more recent fields to emerge in the clinical space, psychedelics have gained significant traction as a potential treatment for various neuropsychiatric diseases. Psychedelic Research at Worldwide Since 2017, Worldwide Clinical Trials have supported a myriad of sponsors leading the way in psychedelic research programs.

Science 98

Science Clinical Trials Trials Clinical Research 98

Alta Sciences

MARCH 4, 2025

Addressing New Challenges in Human Abuse Potential Research The CCALC has held face-to-face meetings in collaboration with industry, academia, and the FDA once every two to three years since inception, and has provided much of the industry perspective on the practical challenges and solutions to assessing abuse and dependence potential.

Clinical Trials 52

Clinical Trials FDA Drug Development Trials 52

Advarra

JUNE 12, 2023

Gene therapy research is exciting and full of promise, but because of the risks involved, it’s also highly regulated, requiring an institutional biosafety committee (IBC) to provide additional oversight and risk assessment. IRBs are tasked with protecting research subject’s rights and welfare. How are IBCs Different from IRBs?

Engineering 98

Engineering Therapies Regulations Research 98

Drug Target Review

AUGUST 16, 2023

Cancer remains a major global health concern, often diagnosed at advanced stages when treatment options and survival rates are limited. Suspicious findings can prompt further evaluation and definitive diagnosis, enabling timely treatment and improved patient outcomes. References 1. Jillian Phallen. DOI:10.1126/scitranslmed.aan2415

DNA 98

DNA Disease Therapies Treatment 98

Drug Target Review

NOVEMBER 17, 2023

Only three of the CAR-NK studies were for the treatment of solid tumours. By themselves, the NK cells showed limited efficacy, but anti-tumour efficacy was observed with co-treatment regimens (eg, monoclonal antibodies, haematopoietic stem cell transplants, whole body irradiation) and multiple dosing (tolerated well by patients).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

Drug Target Review

JULY 10, 2023

The world needs better treatments for neurodegenerative diseases and other brain disorders. Despite decades of research and development, there are currently no drugs that can prevent or cure these diseases and only limited options for symptomatic relief. 2017 Dec 11;9(1). 2017 Sep 1;49(9):1373–84. Alzheimers Res Ther.

Research 52

Research Disease Treatment Drug Development 52

FDA Law Blog: Biosimilars

DECEMBER 4, 2023

A prescription not issued in the usual course of professional treatment or in legitimate, authorized research is not a prescription within the meaning of the CSA and the pharmacist knowingly filling it, along with the prescriber issuing it, is subject to penalties. 21 U.S.C. § 829; 21 C.F.R. Complaint ¶ 55. Complaint ¶ 58.

Pharmacy 139

Pharmacy Government Treatment Compliance 139

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

PPD

JUNE 20, 2024

Acceleration in every step of clinical research is critical to pharmaceutical developers. Yet, today’s clinical research sponsors face significant challenges. Rather than accepting the persistent delays in clinical research as disruptive, yet unavoidable, we believe they underscore the need for greater efficiency.

Clinical Research 52

Clinical Research Research Clinical Trials Pharmaceuticals 52

Drug Target Review

OCTOBER 24, 2023

Live Bacterial Products (LBPs) will provide patients with a desirable, credible, safe and effective treatment option. The human microbiome, a complex ecosystem of microorganisms residing within our bodies, has emerged as a promising frontier in the quest for innovative medical treatments.

Treatment 122

Treatment Pharmaceuticals Pharmacokinetics Production 122

Broad Institute

OCTOBER 15, 2024

He investigated using probiotic bacteria as a possible treatment for C. After completing his PhD in 2017, Brown joined Xavier’s lab as a postdoctoral researcher and has been at the Broad ever since, now as a staff scientist. We spoke with Brown about his experience as both a researcher and a patient in this #WhyIScience Q&A.

Disease 125

Disease Immune Response Research Science 125

The Premier Consulting Blog

JANUARY 14, 2025

Established in 2017 under the 21st Century Cures Act, the OCE brings together multidisciplinary scientific expertise to accelerate the review and approval of drugs, biologics, and medical devices for cancer care.

Clinical Trials 52

Clinical Trials Therapies FDA Trials 52

Drug Target Review

APRIL 19, 2024

After ten years of exciting postdoctoral research around Europe in the astroparticle physics sector, hunting for dark matter at yet another offer from a foreign institution, I chose to create space for my life instead. Pure theoretical research is not in my chords, and I felt uncomfortable not being challenged by data. To participate.

Molecular Biology 111

Molecular Biology Research Pharmaceuticals Small Molecule 111

New Drug Approvals

MAY 8, 2025

Compounds useful as kinase inhibitors (WO 2017/103611 A1). 1] [11] In December 2023, the US Food and Drug Administration (FDA) expanded the indication for pirtobrutinib to include the treatment of adults with chronic lymphocytic leukemia or small lymphocytic leukemia. [7] 5] It is taken by mouth. [1] 2] PATENTS Guisot, N. August 2023).

FDA Approval 52

FDA Approval FDA Therapies Trials 52

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment Drugs FDA Approval 52

Drug Target Review

OCTOBER 17, 2023

To improve its treatment, early diagnosis and appropriate therapeutic strategies are very important. Metabolic changes such as increased arginine levels could serve as biomarkers for detecting cancer at an early stage, which is essential for successful cancer treatment and patient survival. This research was published in Cell.

Regulations 98

Regulations Therapies Treatment Disease 98

New Drug Approvals

NOVEMBER 13, 2023

Vodobatinib can be used for chronic myeloid leukemia (CML) research. Vodobatinib can be used for chronic myeloid leukemia (CML) research [1] [2]. There is a continuing need for effective and safe methods for the treatment of, and delaying the progression of, neurodegenerative diseases, including in the early-stage of the diseases.

Treatment 62

Treatment Disease Therapies Production 62

Alta Sciences

JUNE 27, 2023

Cancer Treatments, Clinical Trials, and the Motivation to Innovate nbartlett Tue, 06/27/2023 - 20:58 Getting to the Heart of Science with Michelle Newby At the heart of science are stories—stories of courage, challenges, successes, lessons, and people. Q: What was your cancer diagnosis and was treatment options were you given?

Clinical Trials 40

Clinical Trials Treatment Trials Science 40

Drug Target Review

AUGUST 24, 2023

We will explore how GDF-15 impacts the tumour microenvironment and hinders the infiltration of T cells into the tumour, as well as the implications of neutralising GDF-15 to reverse its inhibitory effects and sensitise tumours to anti-PD-1 treatment. T-cell infiltration is a prerequisite for responses to checkpoint inhibitors.

Treatment 98

Treatment Therapies Clinical Development Cell Biology 98

The Pharma Data

NOVEMBER 2, 2020

adults by using blood pressure (BP) thresholds from the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7) and the 2017 American College of Cardiology-American Heart Association (ACC-AHA) BP guidelines. adults) using the 2017 ACC-AHA guideline criteria.

Pharmaceuticals 52

Pharmaceuticals Treatment Disease Research 52

KIF1A

JUNE 17, 2023

Dylan Verden of KIF1A.ORG summarizes newly published KIF1A-related research and highlights progress in rare disease research and therapeutic development. The researchers assessed KIF1A’s speed, distribution, and ability to transport both small and large cargo across these 16 mutations. What’s a pre-print? .

Laboratories 98

Laboratories Therapies Disease Research 98

Drug Target Review

APRIL 3, 2024

Could you share an example of a specific project or research that you have worked on and the impact it has had in your field? This multi-layered mechanism contributes to the development of immunoresistance against current standard-of-care treatments such as checkpoint inhibitors, chemotherapy, or antibody-drug conjugates (ADCs).

Science 105

Science Clinical Development Treatment DNA 105

New Drug Approvals

SEPTEMBER 13, 2024

2] Like other kappa opioid antagonists currently under clinical investigation for the treatment of major depression, its efficacy may be compromised by the countervailing activation of pro-inflammatory cytokines in microglia within the CNS. [7] 2] Aticaprant is taken by mouth. [1] nM vs. 24.0 13] [14] Occupancy was 35% for a 0.5 nM vs. 24.0

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

DrugBank

JUNE 27, 2023

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.

Disease 98

Disease Treatment Drugs Clinical Trials 98

Drug Target Review

JUNE 19, 2024

Our goal is to stand on the shoulders of giants and advance this exciting and new field of medicine, so that it can deliver valuable treatments to patients. Because this programme is still in early research, we are not at a point we can say we definitely know what it is going to work best in setting X or setting Y. SVRA) in April 2017.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

NOVEMBER 7, 2024

This targeted enhancement not only boosts the body’s natural mechanisms but also holds promise for developing novel treatments in immunology, where modulating immune responses can lead to more effective and durable therapeutic outcomes. References 1 Tinoco R, Otero DC, Takahashi AA, Bradley LM. Trends in immunology , 38(5), 323-335.

Disease 52

Disease Immune Response Regulations Engineering 52

The Pharma Data

JANUARY 17, 2021

The companies will evaluate ViGeneron’s proprietary, intravitreally injected vgAAV vectors for delivering a novel therapeutic protein to develop a gene therapy treatment for a highly prevalent eye disease. MUNICH, Germany, Jan. The second, REVeRT vector platform, targets diseases caused by mutations in large genes.

Therapies 40

Therapies Research Virus Disease 40

Drug Target Review

SEPTEMBER 26, 2023

Human derived induced pluripotent stem cells (hiPSCs) have revolutionised research and are increasingly used for toxicology screening and disease modelling. This will be achieved by inducing a seizurogenic phenotype using a known seizurogenic compound, and then determining if these changes are reduced by application epilepsy treatments.

Drugs 111

Drugs FDA Disease Animal Testing 111

The Pharma Data

JANUARY 3, 2021

Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton, today announced that the U.S. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., BOSTON, Jan.

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs 75

Drugs Small Molecule Production Disease 75

Drug Target Review

FEBRUARY 28, 2024

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers.

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

NOVEMBER 27, 2020

27, 2020 — Freezing their eggs or ovarian tissue before breast cancer treatment increases survivors’ chances of having children after recovery, a new study finds. Treatment often includes chemotherapy, which can damage ovarian tissue, and long-term hormone treatment, which can cause early menopause. FRIDAY, Nov.

Treatment 52

Treatment Doctors Research 52

The Pharma Data

DECEMBER 30, 2020

(NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced positive results from the long-term, open-label Phase 3 MOVEMENT trial of AXS-07, Axsome’s novel, oral, multi-mechanistic investigational medicine in the acute treatment of migraine.

Trials 52

Trials Treatment Clinical Trials Therapies 52

The Pharma Data

AUGUST 5, 2020

Following an interim analysis of the phase 2 ELARA trial, researchers found that Kymriah met the primary endpoint of complete response rate (CRR) – a standard measure of response to therapy in FL patients. The therapy is a one-time treatment created individually for each patient using their own T cells.

Therapies 52

Therapies Trials Treatment FDA 52

The Pharma Data

JANUARY 11, 2021

The agency previously granted the gene therapy Orphan Drug and Rare Pediatric Disease designations in 2017. Patients receiving the infusion did not achieve statistically significant muscle function following 48 weeks of treatment. Source link.

Therapies 52

Therapies Trials FDA Treatment 52